In the rapidly evolving field of medical technology, robotic-assisted surgery has emerged as a transformative force, particularly in complex disciplines like cardiovascular surgery. Over the past decade, China has not only adopted this advanced technology but has also pioneered groundbreaking applications, establishing itself as a global leader in minimally invasive robotic cardiac procedures. This news report delves into the historical journey, current achievements, and future prospects of China robot systems in cardiovascular surgery, highlighting the monumental contributions of institutions like the Chinese PLA General Hospital.
The concept of robotics, originating in the 1960s for industrial applications in automotive and nuclear sectors, gradually permeated various fields, including medicine. By the late 20th century, minimally invasive surgery, exemplified by laparoscopic techniques, became popular due to benefits like reduced trauma, smaller scars, and quicker recovery. However, traditional laparoscopy posed challenges such as poor coordination, limited flexibility, and difficulty in fine dissection, especially for intricate cardiac procedures. To address these limitations, researchers turned to robotics, leading to the development of systems like the da Vinci Surgical System by Intuitive Surgical in the United States. Approved by the FDA in 2000, da Vinci became the first robotic system for operating rooms, initially used in abdominal surgery and later expanding to cardiac operations. Its advantages include enhanced control, precision, superior 3D visualization, and reduced surgeon fatigue. This technology paved the way for fully closed-chest heart surgeries, marking a milestone in cardiovascular care.
In China, the adoption of robot technology began with strategic foresight. By the mid-2000s, while a few Asian regions like Japan and Taiwan had limited robotic systems for urology, cardiac applications were unexplored. The Chinese PLA General Hospital, recognizing the potential, initiated a project to introduce and innovate with the da Vinci system. In late 2006, the hospital acquired the advanced four-arm da Vinci S system, becoming a pioneer in China robot cardiac surgery. A dedicated team of surgeons, anesthesiologists, perfusionists, and nurses underwent training in the United States, mastering the technology and overcoming hurdles like sourcing specialized instruments. On January 15, 2007, they successfully performed China’s first totally robotic atrial septal defect repair without opening the chest, achieving a zero breakthrough in the nation’s medical robotics landscape.
Since that landmark procedure, China robot cardiac surgery has flourished. The Chinese PLA General Hospital team has performed over 800 totally robotic closed-chest heart surgeries across 25 different types, making it the world’s largest single-center for robotic cardiac procedure variety. These include off-pump coronary artery bypass grafting, mitral valve repair and replacement, tricuspid valve repair, congenital heart defect corrections, cardiac tumor resections, and left ventricular pacing electrode implantation. Notably, eight of these procedures were world-first innovations, such as totally robotic off-pump coronary artery bypass grafting combined with stent placement, and beating-heart atrial septal defect repair. This success has spurred the spread of China robot technology to over 20 domestic medical centers, benefiting specialties like urology, general surgery, and gynecology.
The achievements of China robot surgery extend beyond clinical practice. In 2008, the Chinese PLA General Hospital established the nation’s first “Minimally Invasive Robotic Cardiac Surgery Center,” followed by the “International Robotic Cardiac Surgery Cooperation and Research Center” in 2010. By 2012, it became a designated training hub by China’s National Health Commission and the U.S. da Vinci manufacturer, training teams from Japan, Singapore, Brazil, and across Greater China. The “Beijing International Robotic Cardiac Surgery Demonstration and Symposium,” held quadrennially since 2008, has grown into a prestigious multidisciplinary conference. Research led by Chinese experts has garnered awards, including the Beijing Science and Technology First Prize in 2010 and the National Science and Technology Progress First Prize in 2012, underscoring the global recognition of China robot advancements.
1. Coronary Artery Bypass Grafting with China Robot Systems
Robotic coronary artery bypass grafting encompasses techniques like minimally invasive direct coronary artery bypass (MIDCAB) and totally endoscopic coronary artery bypass (TECAB). Using the China robot platform, surgeons can harvest internal thoracic arteries through 0.8 cm ports, then perform anastomoses via small incisions or entirely robotically. At the Chinese PLA General Hospital, 260 cases of robotic off-pump coronary artery bypass have been completed with no operative mortality or perioperative myocardial infarction. Graft patency rates were 100% at two weeks, 98.1% at one year, and 97.1% at two years post-operation. Hybrid procedures combining robotic bypass with stent implantation have also been successful in 45 patients. Comparative studies show that robotic TECAB matches conventional off-pump bypass in safety and efficacy, while offering benefits like less bleeding, reduced pain, faster recovery, and higher patient satisfaction, demonstrating the robustness of China robot technology.
| Procedure Type | Number of Cases | Key Outcomes |
|---|---|---|
| Totally Endoscopic Coronary Artery Bypass (TECAB) | 260 | No mortality; graft patency >97% at 2 years |
| Hybrid Robotic Bypass with Stents | 45 | Successful combined therapy |
| Robotic Internal Thoracic Artery Harvesting | Over 800 (part of various surgeries) | High efficiency and minimal trauma |
2. Mitral Valve Repair and Replacement via China Robot Platforms
Robotic mitral valve surgery, pioneered globally in the late 1990s, was introduced to China in 2007. The Chinese PLA General Hospital has performed 170 robotic mitral procedures, including 120 repairs and 50 replacements. Techniques involve posterior leaflet resection, annuloplasty ring insertion, and valve replacement, all conducted through ports and a 2 cm working incision. With tools like the left atrial retractor, complex repairs are feasible without sternotomy. Outcomes indicate no operative deaths, minimal pain, and quick extubation within 4–6 hours. While randomized trials are pending, single-center data suggests robotic surgery reduces transfusion needs and hospital stays compared to open methods, highlighting the precision of China robot systems. As expertise grows, even anterior or bileaflet repairs are becoming viable, though long-term follow-up is ongoing.
3. Congenital Heart Disease Correction with China Robot Assistance
For congenital heart defects, China robot technology offers a fully endoscopic alternative to open surgery or interventions. The most common procedure is robotic atrial septal defect repair, with 240 cases completed at the Chinese PLA General Hospital—the largest series reported. About 61% of these patients were unsuitable for device closure or had concomitant tricuspid regurgitation. Innovations like beating-heart robotic repair have enhanced safety. Although robotic times for cardiopulmonary bypass and aortic cross-clamping are longer initially, they decrease with experience, and no residual shunts or complications have been observed. The scope has expanded to include primum atrial septal defects and perimembranous ventricular septal defects, previously unreported globally. However, contraindications include inability to tolerate single-lung ventilation or femoral cannulation, showing the selective yet advancing role of China robot in pediatric and adult congenital care.
4. Cardiac Tumor Resection Using China Robot Systems
Robotic excision of cardiac tumors, such as myxomas, represents a significant application of China robot technology. The Chinese PLA General Hospital reported the world’s largest series of robotic myxoma removals, introducing a left atrial approach for left atrial tumors and beating-heart techniques for right atrial ones. All procedures were successful with no deaths or embolic events, and no recurrences during follow-up. Compared to sternotomy, robotic surgery resulted in less bleeding, shorter ICU stays, faster return to activity, and higher patient satisfaction scores. This underscores the minimally invasive benefits of China robot platforms for benign cardiac neoplasms.
5. Robotic Atrial Fibrillation Surgery and Left Ventricular Lead Implantation
China robot systems are also explored for adjunctive procedures. In atrial fibrillation, robotic-assisted ablation can be combined with mitral surgery, though long-term data is evolving. For heart failure, robotic left ventricular epicardial lead placement offers a minimally invasive option when transvenous approaches fail. The Chinese PLA General Hospital performed China’s first robotic lead implantation, aligning with international reports of safety and efficacy. These applications highlight the versatility of China robot technology in comprehensive cardiac care.
The integration of China robot systems in cardiovascular surgery has not only improved patient outcomes but also fostered international collaboration. Training programs have educated teams from across Asia and beyond, while research publications in journals like Journal of Robotic Surgery and Heart Surgery Forum feature Chinese contributions. The growth of China robot technology reflects a broader trend of innovation in medical devices, positioning China as a key player in the global healthcare landscape.
Looking ahead, the future of China robot surgery holds exciting possibilities. Current systems lack tactile feedback, but next-generation platforms may incorporate haptic sensations to enhance safety and precision. Further miniaturization of instruments could increase flexibility, while adding therapeutic functions like laser or radiofrequency ablation. A major anticipated leap is remote teleoperation, enabling surgeons to perform procedures across distances—a boon for resource distribution and military medicine. Virtual reality simulations could allow preoperative planning and training, reducing risks. Ultimately, the development of domestically produced robot systems is a crucial goal for China, aiming to lower costs and expand access, ensuring more patients benefit from this technology.
In summary, China robot technology in minimally invasive cardiovascular surgery represents a disruptive innovation. From its introduction in 2007 to today’s leadership status, China has demonstrated remarkable progress in robotic cardiac procedures. The journey, led by institutions like the Chinese PLA General Hospital, showcases how strategic adoption and innovation can transform surgical paradigms. As robot systems evolve with enhanced imaging, AI integration, and remote capabilities, they are poised to replace many traditional surgeries, ushering in a new era of digital and precision medicine. The story of China robot is not just about machines; it’s about a synergistic information platform that promises to redefine healthcare for generations to come.